Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Double-digit premium hikes are hitting employers hard — and earlier than expected. A new Gallagher survey of 3,700+ firms found 36% saw premium increases of 10% or more in their latest renewal cycle, driven by cancer care, specialty drugs, and surprise billing disputes. With ~160 million Americans covered through work, the affordability crunch is very real.
Employer-sponsored health coverage is under serious financial strain — and the pain arrived ahead of schedule. A new Gallagher benefits survey of more than 3,700 firms reveals that 36% experienced premium increases of 10% or more during their most recent renewal cycle. Benefits experts say back-to-back double-digit hikes for 2026 and 2027 point to deep structural problems, not just a temporary blip.
The culprits are piling up: cancer is the No. 1 cost driver for roughly 7 in 10 firms, with more people being diagnosed at younger ages and treatments running up to $10,000/month. Specialty drug costs are surging beyond GLP-1 demand, and the No Surprises Act — designed to protect patients — has spawned a costly arbitration process that Aetna's president calls a "top-three single driver" of employer cost increases.
Employers are fighting back by self-insuring, rethinking pharmacy benefit manager relationships, and piloting copay-only plans. But relief isn't imminent.
By the Numbers:
Why it matters: With no immediate relief in sight, employers face a tough balancing act — absorbing rising costs without shifting the burden onto workers, all while navigating a volatile and increasingly expensive healthcare landscape.